Literature DB >> 22752343

A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect.

María Gabriela Simesen de Bielke1, Judith Yancoski, Carlos Rocco, Laura E Pérez, Claudio Cantisano, Néstor Pérez, Matías Oleastro, Silvia Danielian.   

Abstract

UNLABELLED: Mutations in the Fas gene (TNFRSF6) are the most common causes of Autoimmune Lymphoproliferative Syndrome (ALPS-FAS).
PURPOSE: In Argentina almost a third of patients with ALPS-FAS present a missense mutation affecting the extracellular cysteine rich domain 2 of Fas, p.Cys107Tyr (C107Y). This change was found in homozygous state in 2 patients from a consanguineous family, and heterozygously, in 3 other patients from 3 unrelated families. In these families, 12 relatives were identified as healthy carriers of the mutation. We sought to test the hypothesis that this mutation actually represents a single haplotype of TNFRSF6.
METHODS: DNAs from ALPS-C107Y patients and their families, as well as from 150 Argentinean control subjects were sequenced for the known higher frequency single nucleotide polymorphisms (SNPs) of TNFRSF6. The C107Y-carriers were also genotyped at 5 microsatellites proximal to the Fas gene locus.
RESULTS: All C107Y alleles presented a unique intragenic haplotype that could be restricted to this group. Extent of haplotype sharing and variability of microsatellite alleles in C107Y chromosomes support the presence of a single haplotype block including the mutation and encompassing 2.395 Mb.
CONCLUSIONS: A founder effect for C107Y has been evidenced in this work and the most common recent ancestor to the patients probably lived 350 years ago. This constitutes the first report of a founder event in ALPS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752343     DOI: 10.1007/s10875-012-9731-y

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  33 in total

1.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop.

Authors:  Joao B Oliveira; Jack J Bleesing; Umberto Dianzani; Thomas A Fleisher; Elaine S Jaffe; Michael J Lenardo; Frederic Rieux-Laucat; Richard M Siegel; Helen C Su; David T Teachey; V Koneti Rao
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Why did they die?

Authors:  F L Black
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

3.  Estimating the age of rare disease mutations: the example of Triple-A syndrome.

Authors:  E Genin; A Tullio-Pelet; F Begeot; S Lyonnet; L Abel
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

4.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

5.  Clinical, immunological, and pathological consequences of Fas-deficient conditions.

Authors:  F Le Deist; J F Emile; F Rieux-Laucat; M Benkerrou; I Roberts; N Brousse; A Fischer
Journal:  Lancet       Date:  1996-09-14       Impact factor: 79.321

6.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

Review 7.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

8.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

9.  A 475 years-old founder effect involving IL12RB1: a highly prevalent mutation conferring Mendelian Susceptibility to Mycobacterial Diseases in European descendants.

Authors:  J Yancoski; C Rocco; A Bernasconi; M Oleastro; L Bezrodnik; C Vrátnica; F Haerynck; S D Rosenzweig
Journal:  Infect Genet Evol       Date:  2009-03-09       Impact factor: 3.342

10.  Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.

Authors:  A Bettinardi; D Brugnoni; E Quiròs-Roldan; A Malagoli; S La Grutta; A Correra; L D Notarangelo
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

View more
  3 in total

Review 1.  Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Pu Li; Ping Huang; Ye Yang; Mu Hao; Hongwei Peng; Fei Li
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  FAS Haploinsufficiency Caused by Extracellular Missense Mutations Underlying Autoimmune Lymphoproliferative Syndrome.

Authors:  María Gabriela Simesen de Bielke; Laura Perez; Judith Yancoski; João Bosco Oliveira; Silvia Danielian
Journal:  J Clin Immunol       Date:  2015-11-12       Impact factor: 8.317

Review 3.  ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.

Authors:  Filippo Consonni; Eleonora Gambineri; Claudio Favre
Journal:  Ann Hematol       Date:  2022-01-20       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.